Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042055 · ClinicalTrials.gov registry record · Phase 2
CP-461 for the Treatment of Crohn's Disease
A Phase 2 study of Crohn's Disease, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 10
- Study locations
NCT00042055 is a Phase 2 study of Crohn's Disease that has completed, run by Astellas Pharma. The registered enrollment target is 30 participants, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (99% lower). The trial reports 10 study locations across 10 states.
The verdict
NCT00042055, a Phase 2 study of Crohn's Disease, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 10
- Study locations
Study Summary
Patients with moderately to severely active Crohn's disease will be treated with oral CP-461 200 mg (2 x 100 mg capsules) twice-daily for 8 weeks. The purpose of this study is to see if CP-461 improves the symptoms of Crohn's disease and/or the patient's quality of life. Patient's safety will be monitored throughout the study.
Conditions Studied
Interventions
- DRUG CP-461
Study Locations (10)
Alabama
- Southern Drug Research - Birmingham
California
- Community Clinical Trials - Orange
Florida
- Florida Medical Research Institute, PA - Gainesville
Georgia
- Atlanta Gastroenterology Associates - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Indiana
- Indianapolis Gastroenterology and Hepatology, Inc. - Indianapolis
Maryland
- Digestive Disease Associates, PA - Columbia
New Jersey
- Atlantic Gastroenterology Associates - Egg Harbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-07 |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00042055
The ClinicalTrials.gov registry entry for NCT00042055 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (99% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which CP-461 is the first listed.
NCT00042055 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Alabama, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00042055 about?
NCT00042055 is a clinical study titled "CP-461 for the Treatment of Crohn's Disease". Patients with moderately to severely active Crohn's disease will be treated with oral CP-461 200 mg (2 x 100 mg capsules) twice-daily for 8 weeks. The purpose of this study is to see if CP-461 improves the symptoms of Crohn's disease and/or the patient's quality of life. Patient's safety will be mo...
What is the current status of trial NCT00042055?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2002-07. Estimated completion is 2003-09.
What conditions does trial NCT00042055 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT00042055?
The interventions under investigation include: CP-461 (DRUG).
Who is sponsoring clinical trial NCT00042055?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00042055 being conducted?
This trial has 10 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
RECRUITING · Phase 2
-
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.